OTCMKTS:EPRSQ

EPIRUS Biopharmaceuticals Competitors

$0.02

0.00 (0.00 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.01

Now: $0.02▼

$0.02

50-Day Range

$0.01

MA: $0.02▼

$0.03

52-Week Range

$0.00

Now: $0.02▼

$0.24

Volume113,076 shs

Average Volume132,482 shs

Market Capitalization$374,233.00

P/E RatioN/A

Dividend YieldN/A

Beta6.03

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Vs. AKAOQ, COTQF, TLOG, AOXG, PPCB, and ANTH

Should you be buying EPRSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to EPIRUS Biopharmaceuticals, including Achaogen (AKAOQ), Cotinga Pharmaceuticals (COTQF), TetraLogic Pharmaceuticals (TLOG), Aoxing Pharmaceutical (AOXG), Propanc Biopharma (PPCB), and Anthera Pharmaceuticals (ANTH).

EPIRUS Biopharmaceuticals vs. Achaogen Stock

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for EPIRUS Biopharmaceuticals and Achaogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EPIRUS Biopharmaceuticals	0	0	0	0	N/A
Achaogen	0	0	0	0	N/A

Earnings & Valuation

This table compares EPIRUS Biopharmaceuticals and Achaogen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Achaogen	$8.73 million	0.15	$-186,510,000.00	N/A	N/A

EPIRUS Biopharmaceuticals has higher earnings, but lower revenue than Achaogen.

Risk & Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its stock price is 503% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 13.1% of EPIRUS Biopharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares EPIRUS Biopharmaceuticals and Achaogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EPIRUS Biopharmaceuticals	N/A	N/A	N/A
Achaogen	N/A	N/A	N/A

EPIRUS Biopharmaceuticals vs. Cotinga Pharmaceuticals Stock

Cotinga Pharmaceuticals (OTCMKTS:COTQF) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Volatility & Risk

Cotinga Pharmaceuticals has a beta of 43.44, meaning that its stock price is 4,244% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its stock price is 503% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cotinga Pharmaceuticals	N/A	N/A	$-2,050,000.00	N/A	N/A
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cotinga Pharmaceuticals	0	0	0	0	N/A
EPIRUS Biopharmaceuticals	0	0	0	0	N/A

Profitability

This table compares Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cotinga Pharmaceuticals	N/A	N/A	N/A
EPIRUS Biopharmaceuticals	N/A	N/A	N/A

Summary

Cotinga Pharmaceuticals beats EPIRUS Biopharmaceuticals on 1 of the 1 factors compared between the two stocks.

EPIRUS Biopharmaceuticals vs. TetraLogic Pharmaceuticals Stock

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EPIRUS Biopharmaceuticals	0	0	0	0	N/A
TetraLogic Pharmaceuticals	0	0	0	0	N/A

Valuation and Earnings

This table compares EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
TetraLogic Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Volatility & Risk

EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its stock price is 503% more volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EPIRUS Biopharmaceuticals	N/A	N/A	N/A
TetraLogic Pharmaceuticals	N/A	N/A	N/A

Summary

EPIRUS Biopharmaceuticals beats TetraLogic Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

EPIRUS Biopharmaceuticals vs. Aoxing Pharmaceutical Stock

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its share price is 503% more volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EPIRUS Biopharmaceuticals	0	0	0	0	N/A
Aoxing Pharmaceutical	0	0	0	0	N/A

Profitability

This table compares EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EPIRUS Biopharmaceuticals	N/A	N/A	N/A
Aoxing Pharmaceutical	N/A	N/A	N/A

Valuation and Earnings

This table compares EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Aoxing Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Summary

EPIRUS Biopharmaceuticals beats Aoxing Pharmaceutical on 1 of the 1 factors compared between the two stocks.

EPIRUS Biopharmaceuticals vs. Propanc Biopharma Stock

Propanc Biopharma (OTCMKTS:PPCB) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares Propanc Biopharma and EPIRUS Biopharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	$-4,740,000.00	N/A	N/A
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Propanc Biopharma and EPIRUS Biopharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	0	0	0	0	N/A
EPIRUS Biopharmaceuticals	0	0	0	0	N/A

Profitability

This table compares Propanc Biopharma and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	N/A	-4,812.81%
EPIRUS Biopharmaceuticals	N/A	N/A	N/A

Risk and Volatility

Propanc Biopharma has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its stock price is 503% more volatile than the S&P 500.

Summary

EPIRUS Biopharmaceuticals beats Propanc Biopharma on 2 of the 2 factors compared between the two stocks.

EPIRUS Biopharmaceuticals vs. Anthera Pharmaceuticals Stock

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EPIRUS Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EPIRUS Biopharmaceuticals	N/A	N/A	N/A
Anthera Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EPIRUS Biopharmaceuticals	0	0	0	0	N/A
Anthera Pharmaceuticals	0	0	0	0	N/A

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its share price is 503% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Summary

EPIRUS Biopharmaceuticals beats Anthera Pharmaceuticals on 1 of the 1 factors compared between the two stocks.